United Kingdom · Question · Written question
HL HL3063
Vorasidenib
Introduced
6 March 2024
Last action
13 March 2024 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
13 March 2024
Summary
To ask His Majesty's Government what assessment they have made of international phase 3 clinical trials which suggest that Vorasidenib could offer a new treatment option for low-grade glioma; and whether they intend to make it available to brain tumour pa
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
6 March 2024
Written question
To ask His Majesty's Government what assessment they have made of international phase 3 clinical trials which suggest that Vorasidenib could offer a new treatment option for low-grade glioma; and whether they intend to make it available to brain tumour pa
Source: Lords
13 March 2024
Answer
If the manufacturer applies for a marketing authorisation in the United Kingdom, the Medicines and Healthcare products Regulatory Agency will consider clinical trial evidence in making a licensing decision. Subject to licensing, the National Institute for...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2024-03-06/HL3063
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1694328
- uk · wq-1694328 · source updated 13 March 2024